Wells Fargo
OLMA icon

Wells Fargo’s Olema Pharmaceuticals OLMA Stock Holding History

Wells Fargo’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$692K Sell
46,433
-37,697
-45% -$839K ﹤0.01% 3964
2025
Q4 		$2.1M Buy
84,130
+38,469
+84% +$685K ﹤0.01% 3388
2025
Q3 		$447K Buy
45,661
+7,446
+19% +$44.7K ﹤0.01% 4384
2025
Q2 		$163K Buy
38,215
+14,976
+64% +$66.8K ﹤0.01% 4888
2025
Q1 		$87.4K Buy
23,239
+514
+2% +$2.58K ﹤0.01% 5171
2024
Q4 		$132K Buy
22,725
+5,958
+36% +$59.5K ﹤0.01% 5041
2024
Q3 		$200K Buy
16,767
+457
+3% +$5.84K ﹤0.01% 4583
2024
Q2 		$176K Buy
16,310
+6,630
+68% +$71.9K ﹤0.01% 4597
2024
Q1 		$110K Buy
9,680
+1,222
+14% +$15.8K ﹤0.01% 4839
2023
Q4 		$119K Buy
8,458
+1,733
+26% +$23.3K ﹤0.01% 4795
2023
Q3 		$83.1K Sell
6,725
-3,568
-35% -$36.4K ﹤0.01% 4893
2023
Q2 		$92.9K Buy
10,293
+10,047
+4,084% +$60.7K ﹤0.01% 5090
2023
Q1 		$854 Buy
246
+4
+2% +$16 ﹤0.01% 6425
2022
Q4 		$593 Buy
242
+6
+3% +$17 ﹤0.01% 6344
2022
Q3 		$1K Buy
236
+36
+18% +$153 ﹤0.01% 6416
2022
Q2 		$1K Sell
200
-1,588
-89% -$5.04K ﹤0.01% 6563
2022
Q1 		$8K Sell
1,788
-8,833
-83% -$48.7K ﹤0.01% 6347
2021
Q4 		$99K Buy
10,621
+9,866
+1,307% +$204K ﹤0.01% 5643
2021
Q3 		$21K Buy
+755
New +$20.4K ﹤0.01% 5965
2021
Q2 		– Sell
-3,839
Closed -$128K – 7281
2021
Q1 		$128K Buy
3,839
+3,809
+12,697% +$163K ﹤0.01% 5373
2020
Q4 		$1K Buy
+30
New +$1.41K ﹤0.01% 6366

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wells Fargo's OLMA Position: Q1 2026 in Review

Wells Fargo reduced its Olema Pharmaceuticals (OLMA) stake by 45% in Q1 2026, selling an estimated $839K and leaving 46,433 shares worth $692K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Wells Fargo first reported a position in OLMA in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.1M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Wells Fargo held 46,433 shares of Olema Pharmaceuticals worth $692K as of Q1 2026.
  • Wells Fargo sold 37,697 Olema Pharmaceuticals shares in Q1 2026, an estimated $839K.
  • Olema Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3964 holding.
  • Wells Fargo first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Wells Fargo's Olema Pharmaceuticals position peaked at $2.1M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.